PepVault
/ database / GLP-1 / Glucagon Dual

Survodutide

Also: BI 456906

Dual GLP-1/glucagon agonist — competes with retatrutide on potency.

Evidence
emerging
Legal status
research only
Half-life
~6-7 days
Routes
subq
View on Limitless LifeAdd to compare
What it is

Survodutide combines GLP-1 appetite suppression with glucagon-driven energy expenditure and lipolysis. Phase 2 data show ~19% mean weight loss at 46 weeks.

Mechanism

Co-agonist of GLP-1 and glucagon receptors — adds energy expenditure on top of appetite suppression.

Outcomes it's matched to
Safety

Nausea, vomiting; cardiovascular monitoring required due to glucagon activity.

  • Pregnancy
  • Personal/family MTC
Legal context

Not approved. Phase 3 ongoing.

1:1 GUIDANCE

Have questions about this peptide?

Get free 1:1 guidance from a peptide professional before you start. They'll help you think through dosing, stacking, and whether this fits your goals.

REQUEST A CALL →
PepVault

An outcome-driven reference for modern peptides. Educational only — not medical advice, not a sales platform, not affiliated with any clinic.

Disclaimer: PepVault is an educational resource. Nothing on this site is medical advice. Many peptides discussed are research compounds and are not approved by the FDA or equivalent agencies. Always consult a qualified clinician before starting any protocol.

© 2026 PepVault